Calidi Biotherapeutics Inc. announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The company's presentation will focus on its proprietary RedTail platform, an engineered enveloped oncolytic virus technology designed for systemic administration to target metastatic cancer sites. The RedTail platform represents a significant advancement in immuno-oncology by addressing one of the major challenges in virotherapy: immune system clearance of therapeutic viruses before they reach tumor sites.
This technology is engineered to shield the virus from immune detection, allowing it to effectively reach distant metastatic locations, induce tumor lysis, and deliver therapeutic genetic medicines directly to cancer cells throughout the body. Calidi's lead candidate from the RedTail platform is currently in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. The company's approach could potentially transform cancer treatment by enabling systemic delivery of oncolytic viruses, moving beyond the limitations of localized administration that have constrained previous virotherapy approaches.
The availability of an on-demand presentation starting September 5 at 7 a.m. ET provides investors and the medical community with early access to detailed information about Calidi's technology and development progress. This presentation comes at a critical time as the company advances its clinical-stage programs, including both systemic and intratumoral administration approaches for various cancer indications. For investors seeking additional information, the company maintains a newsroom at https://ibn.fm/CLDI where updates and developments are regularly posted.
The conference presentation represents an important opportunity for Calidi to demonstrate the potential of its platform technology to address significant challenges in metastatic cancer treatment and position itself within the competitive immuno-oncology landscape. The RedTail platform's ability to overcome immune clearance barriers could enable more effective treatment of metastatic cancers that have historically been difficult to target with traditional virotherapy approaches. This development matters because it represents a potential paradigm shift in cancer treatment, moving from localized virus administration to systemic delivery that could reach cancer cells throughout the body.
The implications of this announcement extend beyond investor relations to potential clinical applications. If successful, Calidi's technology could provide new treatment options for patients with metastatic cancers who have limited therapeutic alternatives. The company's focus on high-unmet-need cancers like non-small cell lung cancer and ovarian cancer addresses areas where current treatments often fall short. As Calidi advances its clinical programs, the medical community will be watching closely to see if this engineered virus technology can deliver on its promise to transform metastatic cancer treatment through systemic administration.
